OCTOBER 8, 2020 (All time EST)

9:00 – 9:10 AM

Welcome and Introductions

Daniel Auclair, PhD, MMRF & C. Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center 

9:10 – 9:30 AM

MRD in 2020: BMCTN consensus document

Luciano Costa, MD, University of Alabama at Birmingham 

9:30 – 9:50 AM

New trials with MRD focus. GRIFFIN, FORTE, ENDURANCE, MASTER, MAHATTAN

Benjamin Derman, MD, University of Chicago

9:50 – 10:10 AM

New MRD technologies and future regulatory paths

Dickran Kazandjian, MD, NCI and FDA 

DEBATES

10:10 – 10:30 AM

Session 1: Should sustained MRD negativity be used to stop the treatment? 

Yes: Nina Shah, UCSF and MMRC Steering Committee 

No: Ajai Chari, MD, Icahn School of Medicine at Mount Sinai and MMRC Steering Committee 

10:30 – 10:50 AM

Session 2: Should MRD+ be used to re-initiate the treatment?

Yes: Elisabet Manasanch, MD Anderson  

No: Amrita Krishnan, MD, City of Hope and MMRC Steering Committee

10:50 – 11:10 AM

Session 3: Should MRD be used to guide delayed ASCT?

Continue with transplant: Noa Biran, MD, John Theurer Cancer Center

Hold off transplant: Paul Richardson, MD, DFCI 

PANEL DISCUSSION

11:10 – 11:35 AM

MRD future directions

Moderator: Hearn J. Cho, MD, Ph.D., MMRF and Mount Sinai

• C. Ola Landgren, MD, PhD 

• Gareth Morgan, MD, PhD, NYU

• Ruben Niesvizky, MD, New York-Presbyterian/Weill Cornell Medicine

• Suzanne Lentzsch, MD, PhD, Columbia University Irving Medical Center

• James Hoffman, MD, University of Miami/Sylvester Comprehensive Cancer Center

• Sundar Jagannath, MD, Mount Sinai

• Noa Biran, MD, John Theurer Cancer Center

11:35 – 11:40 AM

Summary and Adjournment

C. Ola Landgren, MD, Memorial Sloan Kettering Cancer Center

Hearn J. Cho, MD, Ph.D., MMRF and Mount Sinai